Profile data is unavailable for this security.
About the company
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
- Revenue in SEK (TTM)165.88m
- Net income in SEK-844.88m
- Incorporated2007
- Employees166.00
- LocationHansa Biopharma ABScheelevagen 22,P.O. Box 785LUND 220 07SwedenSWE
- Phone+46 46165670
- Fax+46 46127775
- Websitehttps://www.hansabiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moberg Pharma AB (publ) | 0.00 | -21.09m | 969.83m | -- | -- | 1.56 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -179.67m | 1.01bn | 26.00 | -- | 1.81 | -- | -- | -7.02 | -7.02 | 0.00 | 22.19 | 0.00 | -- | -- | 0.00 | -26.60 | -18.38 | -28.03 | -19.26 | -- | -- | -- | -- | 4.36 | -- | 0.0504 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vistin Pharma ASA | 435.58m | 45.36m | 1.04bn | 79.00 | 22.83 | 3.23 | 16.54 | 2.38 | 1.03 | 1.03 | 9.88 | 7.28 | 1.09 | 2.16 | 7.75 | -- | 11.33 | 1.73 | 14.64 | 2.11 | 59.70 | 59.01 | 10.41 | 2.36 | 1.30 | 6.81 | -- | -- | 52.37 | 17.11 | 1,067.85 | -- | -0.2357 | -- |
| Cereno Scientific AB | 0.00 | -48.11m | 1.13bn | 5.00 | -- | 4.35 | -- | -- | -0.241 | -0.241 | 0.00 | 0.9258 | 0.00 | -- | -- | 0.00 | -19.22 | -16.81 | -20.75 | -18.26 | -- | -- | -- | -- | -- | -12.92 | 0.1734 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -123.07m | 1.14bn | 8.00 | -- | 3.86 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Diamyd Medical AB | 282.00k | -120.18m | 1.14bn | 26.00 | -- | 5.90 | -- | 4,049.89 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| SyntheticMR AB (publ) | 89.21m | 10.01m | 1.18bn | 37.00 | 115.34 | 10.08 | 72.32 | 13.18 | 0.2445 | 0.2445 | 2.17 | 2.80 | 0.6599 | -- | 1.61 | 2,411,162.00 | 7.41 | 7.19 | 8.89 | 8.85 | 105.78 | 106.74 | 11.22 | 9.08 | -- | 14.13 | 0.0107 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 26.79 | -- |
| Arcticzymes Technologies ASA | 118.19m | 18.60m | 1.30bn | 61.00 | 69.70 | 4.25 | 52.28 | 11.04 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
| Hansa Biopharma AB | 165.88m | -844.88m | 1.43bn | 166.00 | -- | -- | -- | 8.64 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Photocure ASA | 497.52m | 265.33k | 1.47bn | 106.00 | 7,576.60 | 3.06 | 52.77 | 2.95 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
| BioInvent International AB | 71.46m | -330.30m | 1.63bn | 111.00 | -- | 1.24 | -- | 22.79 | -5.02 | -5.02 | 1.09 | 19.90 | 0.0459 | -- | 5.16 | 643,792.80 | -21.23 | -17.50 | -22.40 | -18.64 | -- | -- | -462.22 | -131.63 | 14.77 | -- | 0.0174 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Devyser Diagnostics AB | 169.30m | -53.60m | 1.68bn | 118.00 | -- | 4.36 | -- | 9.91 | -3.31 | -3.31 | 10.46 | 23.65 | 0.335 | 1.59 | 5.53 | 1,434,746.00 | -10.65 | -8.97 | -12.00 | -10.15 | 85.53 | 80.14 | -31.78 | -23.91 | 5.11 | -- | 0.1626 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Genovis AB | 158.23m | 61.50m | 1.70bn | 37.00 | 27.62 | 8.90 | 23.85 | 10.74 | 0.9394 | 0.9394 | 2.42 | 2.91 | 0.7203 | -- | -- | 4,276,514.00 | 27.99 | 18.56 | 30.74 | 21.45 | 72.20 | 65.51 | 38.87 | 23.88 | -- | -- | -- | -- | 54.54 | 35.56 | 449.56 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 57.50m | -326.80m | 1.74bn | 27.00 | -- | 3.19 | -- | 30.22 | -1.28 | -1.28 | 0.224 | 1.86 | 0.087 | 16.92 | 3.59 | 2,129,630.00 | -49.44 | -33.02 | -55.92 | -36.46 | 80.87 | -- | -568.00 | -357.72 | 3.32 | -- | 0.1688 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Nanoform Finland Oyj | 29.98m | -242.52m | 1.86bn | 165.00 | -- | 2.38 | -- | 62.07 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Vicore Pharma Holding AB | 0.00 | -310.94m | 1.86bn | 24.00 | -- | 4.09 | -- | -- | -3.24 | -3.24 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -74.40 | -58.65 | -83.09 | -65.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Hansa Biopharma AB's reporting currency: Swedish Krona SEK
47.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 11 Apr 2024 | 12.21m | 23.18% |
| Braidwell LPas of 12 Apr 2024 | 6.11m | 11.61% |
| Fj�rde AP-fondenas of 30 Jun 2023 | 2.21m | 4.19% |
| Tredje AP-fondenas of 30 Jun 2023 | 1.39m | 2.64% |
| Handelsbanken Fonder ABas of 30 Jun 2023 | 879.18k | 1.67% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 30 Jun 2023 | 799.75k | 1.52% |
| Heights Capital Management, Inc.as of 31 Dec 2022 | 667.17k | 1.27% |
| SEB Investment Management ABas of 28 Mar 2024 | 335.58k | 0.64% |
| Teknik Innovation Norden Fonder ABas of 30 Jun 2021 | 290.00k | 0.55% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 285.73k | 0.54% |
More ▼
Data from 30 Jun 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
